Rapid Immunoassay Distinguishes Between COVID-19 and Seasonal Flu Infections In 10 Minutes

Respiratory infections such as influenza and COVID-19 often present with nearly identical symptoms, making it difficult for clinicians to quickly determine the cause. Timely diagnosis is essential, as treatment options and infection control measures differ significantly depending on the virus involved. Now, a new diagnostic test can detect and differentiate between these infections from a single sample in just minutes, helping guide faster clinical decisions.

QuidelOrtho (San Diego, CA, USA) has launched the QUICKVUE Influenza + SARS Test, a CLIA-waived and 510(k)–cleared rapid immunoassay. The device allows for simultaneous detection and differentiation of influenza A, influenza B, and SARS-CoV-2 antigens from a single nasal swab sample. Results are available in as fast as 10 minutes, enabling clinicians to distinguish COVID-19 from seasonal flu infections at the point of care.

Designed for use in physician office labs, urgent care centers, emergency departments, pharmacies, and decentralized hospital labs, the QUICKVUE Influenza + SARS Test supports healthcare providers during seasonal surges of respiratory illness. With streamlined processing, a clear result window, and a cost-effective design, the test ensures efficient workflows and affordable access.

The test adds to QuidelOrtho's portfolio of respiratory solutions, including the SOFIA 2 Flu + SARS Antigen FIA, by offering a visually read alternative to its instrumented solutions, strengthening its position in point-of-care respiratory testing. The test is available across the United States through the company’s established distribution network, though it is intended strictly for professional use rather than at-home testing.

“Physician office labs and urgent care centers are on the front lines of respiratory illness diagnosis. With the QUICKVUE Influenza + SARS Test, we're equipping healthcare providers with a reliable, affordable, and efficient tool to differentiate between COVID-19 and influenza in minutes. This innovation reflects QuidelOrtho's commitment to supporting healthcare professionals with cost-effective solutions that streamline clinical decisions and help manage seasonal surges in respiratory infections,” said Tammi Ranalli, PhD, Senior Vice President, Molecular Diagnostics and Point of Care Business Units, QuidelOrtho.